Key Events This Week
1 June: Formation of Golden Cross signalling potential bullish breakout
2 June: Upgrade to Hold rating by MarketsMOJO on technical and valuation improvements
5 June: Stock closes the week lower at Rs.169.35 (-3.53%)
Jun 23, 03:30 PM
BSE+NSE Vol: 23.56 k

Nath Bio-Genes (India) Ltd, a micro-cap player in the Other Agricultural Products sector, has seen its investment rating downgraded from Hold to Sell as of 22 June 2026. This adjustment reflects a complex interplay of factors including a shift in technical indicators, subdued financial trends, valuation considerations, and overall quality assessments. Despite a modest uptick in share price, the company’s long-term fundamentals and market performance continue to raise concerns for investors.
Read full news article
Nath Bio-Genes (India) Ltd, a micro-cap player in the Other Agricultural Products sector, has seen its investment rating upgraded from Sell to Hold as of 15 June 2026. This revision reflects a nuanced assessment across four key parameters: quality, valuation, financial trend, and technicals. While the company continues to face challenges in long-term growth and profitability, recent technical indicators and valuation metrics have improved sufficiently to warrant a more cautious but optimistic stance.
Read full news article
1 June: Formation of Golden Cross signalling potential bullish breakout
2 June: Upgrade to Hold rating by MarketsMOJO on technical and valuation improvements
5 June: Stock closes the week lower at Rs.169.35 (-3.53%)

Nath Bio-Genes (India) Ltd has been downgraded from a Hold to a Sell rating by MarketsMOJO as of 8 June 2026, reflecting concerns over its stagnant financial performance, weak long-term fundamentals, and consistent underperformance against market benchmarks. Despite a very attractive valuation, the company’s deteriorating financial trends and technical indicators have prompted a cautious stance from analysts.
Read full news article
Nath Bio-Genes (India) Ltd, a micro-cap player in the Other Agricultural Products sector, has seen its investment rating upgraded from Sell to Hold as of 1 June 2026. This change reflects a nuanced reassessment across four key parameters: quality, valuation, financial trend, and technicals. Despite persistent challenges in long-term fundamentals, recent technical signals and valuation metrics have improved sufficiently to warrant a more cautious but optimistic stance.
Read full news article
The 50-day moving average for Nath Bio-Genes (India) Ltd has crossed above the 200-day moving average, signalling a golden cross on 1 Jun 2026. While this technical event often suggests a shift towards bullish momentum, the broader technical and fundamental context presents a more nuanced picture that merits careful analysis.
Read full news article
Nath Bio-Genes (India) Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 07 Apr 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 22 May 2026, providing investors with an up-to-date view of the company's performance and outlook.
Read full news article
Nath Bio-Genes (India) Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 07 Apr 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 11 May 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.
Read full news article